Literature DB >> 2991060

Mother-to-child transmission of human T-cell leukemia virus type-I.

S Hino, K Yamaguchi, S Katamine, H Sugiyama, T Amagasaki, K Kinoshita, Y Yoshida, H Doi, Y Tsuji, T Miyamoto.   

Abstract

By screening sera obtained from 5015 pregnant women under the care of 9 gynecology/obstetrics departments of hospitals or clinics in Nagasaki City and its surrounding areas, 187 were found to be positive for antibody against adult T-cell leukemia-associated antigen (ATLA). The prevalence of seropositive pregnant women was consistent with that of blood donors in the age group of 16 to 29 years, taken as controls. Essentially all cord blood samples (113/115) of babies born from these seropositive mothers were positive for anti-ATLA of IgG class. These IgG antibodies in the babies diminished rapidly after delivery, and were detectable only in 3 cases at 2, 3, and 5 months of ages out of 38 babies up to 21 months. None of 115 cord bloods so far tested was positive either for anti-ATLA of IgM class or for ATLA-bearing lymphocytes after short-term cultures of the rosette-forming T-lymphocytes. Two of the babies born from 38 seropositive mothers were found seroconverted between the ages of 12 and 19 months. Three out of 20 elder siblings were found seropositive at ages of 3 to 6 years. The seropositive rate in these siblings was significantly higher than that of controls. Moreover, 12 out of 13 mothers traced back from seropositive students were found seropositive. These data indicate strongly that HTLV-I is transmitted from seropositive mothers to their children as a major pathway.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2991060

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  59 in total

1.  Seroprevalence and demographic characteristics of HTLV-I among blood donors in Taiwan: 1996-1999.

Authors:  S C Lu; C L Kao; L T Chin; J W Chen; C M Yang; J H Chang; S C Hsu; A C Chang; B H Chen
Journal:  Int J Hematol       Date:  2001-10       Impact factor: 2.490

2.  Transmission of human T-cell leukemia virus type 1 to mice.

Authors:  J Fang; S Kushida; R Feng; M Tanaka; T Kawamura; H Abe; N Maeda; M Onobori; M Hori; K Uchida; M Miwa
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  Screening for prolonged incubation of HTLV-I infection in British and Jamaican relatives of British patients with tropical spastic paraparesis.

Authors:  J K Cruickshank; J H Richardson; O S Morgan; J Porter; P Klenerman; J Knight; A L Newell; P Rudge; A G Dalgleish
Journal:  BMJ       Date:  1990-02-03

4.  Co-infection with GB virus C in an area of high endemicity for human T-lymphotropic virus type I in Japan.

Authors:  S Chiyoda; J Inoue; H Okamoto
Journal:  Infection       Date:  1997 Mar-Apr       Impact factor: 3.553

Review 5.  The origin and evolution of human T-cell lymphotropic virus types I and II.

Authors:  Y Suzuki; T Gojobori
Journal:  Virus Genes       Date:  1998       Impact factor: 2.332

Review 6.  Adult T-cell leukemia-lymphoma.

Authors:  S M Neely
Journal:  West J Med       Date:  1989-05

7.  Immunogenetics and the Pathological Mechanisms of Human T-Cell Leukemia VirusType 1- (HTLV-1-)Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP).

Authors:  Mineki Saito
Journal:  Interdiscip Perspect Infect Dis       Date:  2010-02-10

Review 8.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

9.  Induction of antibody responses that neutralize human T-cell leukemia virus type I infection in vitro and in vivo by peptide immunization.

Authors:  Y Tanaka; R Tanaka; E Terada; Y Koyanagi; N Miyano-Kurosaki; N Yamamoto; E Baba; M Nakamura; H Shida
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

10.  Identification and mapping of functional domains on human T-cell lymphotropic virus type 1 envelope proteins by using synthetic peptides.

Authors:  Y Sagara; Y Inoue; H Shiraki; A Jinno; H Hoshino; Y Maeda
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.